Please use this identifier to cite or link to this item: https://doi.org/10.1177/1078155212457806
DC FieldValue
dc.titleVisualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy
dc.contributor.authorChen, C.
dc.contributor.authorChan, A.
dc.contributor.authorYap, K.
dc.date.accessioned2014-10-29T02:01:03Z
dc.date.available2014-10-29T02:01:03Z
dc.date.issued2013-06
dc.identifier.citationChen, C.,Chan, A.,Yap, K. (2013-06). Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy. Journal of Oncology Pharmacy Practice 19 (2) : 111-120. ScholarBank@NUS Repository. <a href="https://doi.org/10.1177/1078155212457806" target="_blank">https://doi.org/10.1177/1078155212457806</a>
dc.identifier.issn10781552
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/106508
dc.description.abstractPurpose: Febrile neutropenia is a serious complication among cancer patients receiving myelosuppressive chemotherapy. Patient-specific risk factors, chemotherapy-related and disease-related characteristics can affect the clinical outcome and management of febrile neutropenia. Although many factors have been identified, they vary among different patient populations. We identified clinically-relevant febrile neutropenia predictors in Asian cancer patients through visualization of these factors. Methods: A single-centered, retrospective study was conducted from May to July 2011 at a local cancer center. Demographics and risk factor data were collated from electronic health records and four cancer registries. Data were summarized using descriptive statistics. Additionally, potential febrile neutropenia predictors were identified using categorical principal component and multiple correspondence analyses. Results: A total of 583 patients were analyzed. Majority was females (79%), Chinese (75%) and diagnosed with breast cancers (60%). Six risk factors were identified as potential predictors: types of cancer (16.9-19.8% of variance), chemotherapy regimen (anthracycline-based 11.8-12.9%, taxane-based 8.1%), liver function tests (alanine transaminase 8.6%, alkaline phosphatase 4.0%), renal function tests (serum creatinine 3.1%), prior granulocyte colony stimulating factor use (5.6%) and diabetes mellitus (6.6-6.9%). In terms of cancer types, lymphomas were more predictive than breast cancers. Conclusion: From our knowledge, this is the first study that has identified clinically-relevant febrile neutropenia predictors in Asian cancer patients through visualization of their risk factors. The use of these predictors to identify patients at risk for adverse reactions, such as FN, can allow clinicians to optimize prophylactic granulocyte colony stimulating factor usage in these patients. © The Author(s) 2012.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1177/1078155212457806
dc.sourceScopus
dc.subjectClinical predictors
dc.subjectdata reduction techniques
dc.subjectfebrile neutropenia
dc.subjectmultiple correspondence analysis
dc.subjectprincipal component analysis
dc.typeArticle
dc.contributor.departmentPHARMACY
dc.description.doi10.1177/1078155212457806
dc.description.sourcetitleJournal of Oncology Pharmacy Practice
dc.description.volume19
dc.description.issue2
dc.description.page111-120
dc.description.codenJOPPF
dc.identifier.isiutNOT_IN_WOS
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.